The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I and pharmacokinetic trial of the antitemolerase agent KML001 (KML) and cisplatin (CDDP) in advanced solid tumors.
Martin J. Edelman
Consultant or Advisory Role - Kominox
Honoraria - Kominox
Josephine Louella Feliciano
No relevant relationships to disclose
Miroslav Styblo
No relevant relationships to disclose
Tao Liu
No relevant relationships to disclose
Rena G. Lapidus
No relevant relationships to disclose
Jesse Saunders
No relevant relationships to disclose
Joga Gobburu
No relevant relationships to disclose